Research activity information

• SAMD4 represses VGLL4 mRNA to activate TEAD and promote cancer progression.

  Junji Otani, Miki Nishio, Riko Tokita, Hiroki Hikasa, Makoto Nishimori, Shingo Dan, Isao Naguro, Hidenori Ichijo, Masanori Miyanishi, Takehiko Sasaki, Hiroshi Nishina, Tak Wah Mak, Tomohiko Maehama, Akira Suzuki

  The transcriptional cofactors YAP1 and TAZ regulate target gene expression by binding to the transcription factor TEAD. Due to their roles in cancer initiation, progression, and drug resistance, YAP1 and TAZ are promising targets for cancer therapy. SAMD4A/B are RNA-binding proteins that are broadly expressed across human tissues, but few of their molecular targets and biological functions have been identified. In Drosophila, the SAMD4A/B homolog Smaug participates in early embryonic development by disrupting the stability and translation of maternal mRNA. To discover targets inhibiting the YAP1/TAZ-TEAD oncogenic transcription program, we screened a whole-genome siRNA library and identified siSAMD4B as potently suppressing TEAD activity in human cancer cells. We showed that SAMD4A/B increased TEAD activity by destabilizing and repressing the translation of VGLL4 mRNA, promoting cancer progression in vitro. Conversely, inhibiting either SAMD4A or SAMD4B elevated VGLL4 mRNA, which suppressed TEAD activity and inhibited cancer progression. Notably, transgenic mice expressing liver-specific SAMD4B exhibited accelerated development of intrahepatic cholangiocarcinomas in an Nf2-deficient background. These tumors appeared in the mutants at one week of age and caused death due to hepatic failure by 100 days. Thus, SAMD4A/B may be a promising target for anticancer drugs designed to inhibit TEAD activation.

  Apr. 2026, Oncogene, English, International magazine

  Scientific journal


• Alteration of long- and short-term hematopoietic stem cell ratio causes myeloid-biased hematopoiesis.

  Katsuyuki Nishi, Taro Sakamaki, Akiomi Nagasaka, Kevin Shuolong Kao, Kay Sadaoka, Masahide Asano, Nobuyuki Yamamoto, Akifumi Takaori-Kondo, Masanori Miyanishi

  Myeloid-biased hematopoiesis is a well-known age-related alteration. Several possibilities, including myeloid-biased hematopoietic stem cell (HSC) clones, may explain this. However, the precise mechanisms remain controversial. Utilizing the Hoxb5 reporter system to prospectively isolate long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs), we found that young and aged LT-HSCs co-transplanted into the same recipients demonstrated nearly equivalent myeloid lineage output, contrary to the theory of myeloid-biased HSC clones. Transcriptomics indicated no significant myeloid gene enrichment in aged LT-HSCs compared to their young counterparts. Instead, transplanting reconstituted young HSCs with the ratio of LT/ST-HSCs seen in aged mice can significantly skew the lineage output to myeloid cells. In addition, while the niche environment in the bone marrow minimally affects myeloid-biased hematopoiesis, aged thymi and spleens substantially hinder lymphoid hematopoiesis, resulting in further myeloid domination. Thus, we demonstrate that myeloid-biased hematopoiesis in aged mice originates due to alteration of the ratio between LT-HSCs and ST-HSCs rather than in heterogeneous HSC clones with various cell fates.

  Aug. 2025, eLife, 13, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 慢性活動性EBウイルス感染症から発生したNKリンパ腫細胞における新規DDX3Xスプライス変異の同定

  井上 翔太郎, 田村 彰広, 藤川 朋子, 花房 宏昭, 酒巻 太郎, 西村 明紘, 中谷 尚子, 長坂 明臣, 山本 暢之, 野津 寛大, 宮西 正憲

  (一社)日本血液学会, Oct. 2024, 日本血液学会学術集会, 86回, O2 - 1, English


• CXCR2 inhibition in G-MDSCs enhances CD47 blockade for melanoma tumor cell clearance.

  Allison Banuelos, Allison Zhang, Hala Berouti, Michelle Baez, Leyla Yılmaz, Nardin Georgeos, Kristopher D Marjon, Masanori Miyanishi, Irving L Weissman

  The use of colony-stimulating factor-1 receptor (CSF1R) inhibitors has been widely explored as a strategy for cancer immunotherapy due to their robust depletion of tumor-associated macrophages (TAMs). While CSF1R blockade effectively eliminates TAMs from the solid tumor microenvironment, its clinical efficacy is limited. Here, we use an inducible CSF1R knockout model to investigate the persistence of tumor progression in the absence of TAMs. We find increased frequencies of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the bone marrow, throughout circulation, and in the tumor following CSF1R deletion and loss of TAMs. We find that G-MDSCs are capable of suppressing macrophage phagocytosis, and the elimination of G-MDSCs through CXCR2 inhibition increases macrophage capacity for tumor cell clearance. Further, we find that combination therapy of CXCR2 inhibition and CD47 blockade synergize to elicit a significant anti-tumor response. These findings reveal G-MDSCs as key drivers of tumor immunosuppression and demonstrate their inhibition as a potent strategy to increase macrophage phagocytosis and enhance the anti-tumor efficacy of CD47 blockade in B16-F10 melanoma.

  Jan. 2024, Proceedings of the National Academy of Sciences of the United States of America, 121(5) (5), e2318534121, English, International magazine

  Scientific journal


• Isolation Method for Long-Term and Short-Term Hematopoietic Stem Cells.

  Katsuyuki Nishi, Akiomi Nagasaka, Taro Sakamaki, Kay Sadaoka, Masanori Miyanishi

  Self-renewal capacity and multi-lineage differentiation potential are generally regarded as the defining characteristics of hematopoietic stem cells (HSCs). However, numerous studies have suggested that functional heterogeneity exists in the HSC compartment. Recent single-cell analyses have reported HSC clones with different cell fates within the HSC compartment, which are referred to as biased HSC clones. The mechanisms underlying heterogeneous or poorly reproducible results are little understood, especially regarding the length of self-renewal when purified HSC fractions are transplanted by conventional immunostaining. Therefore, establishing a reproducible isolation method for long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs), defined by the length of their self-renewal, is crucial for overcoming this issue. Using unbiased multi-step screening, we identified a transcription factor, Hoxb5, which may be an exclusive marker of LT-HSCs in the mouse hematopoietic system. Based on this finding, we established a Hoxb5 reporter mouse line and successfully isolated LT-HSCs and ST-HSCs. Here we describe a detailed protocol for the isolation of LT-HSCs and ST-HSCs using the Hoxb5 reporter system. This isolation method will help researchers better understand the mechanisms of self-renewal and the biological basis for such heterogeneity in the HSC compartment.

  May 2023, Journal of visualized experiments : JoVE, (195) (195), English, International magazine

  Scientific journal


• Identification of the minimum requirements for successful haematopoietic stem cell transplantation.

  Katsuyuki Nishi, Taro Sakamaki, Kay Sadaoka, Momo Fujii, Akifumi Takaori-Kondo, James Y Chen, Masanori Miyanishi

  Historically, defining haematopoietic subsets, including self-renewal, differentiation and lineage restriction, has been elucidated by transplanting a small number of candidate cells with many supporting bone marrow (BM) cells. While this approach has been invaluable in characterising numerous distinct subsets in haematopoiesis, this approach is arguably flawed. The haematopoietic stem cell (HSC) has been proposed as the critical haematopoietic subset necessary for transplantation. However, due to the presence of supporting cells, the HSC has never demonstrated sufficiency. Utilising the homeobox B5 (Hoxb5)-reporter system, we found that neither long-term (LT) HSCs nor short-term (ST) HSCs alone were sufficient for long-term haematopoietic reconstitution. Critically, reconstitution can be rescued by transplanting combined LT- and ST-HSCs, without supporting cells; a fraction we term the 'Minimum Subset for Transplantation' (MST). The MST accounts for only 0·005% of nucleated cells within mouse BM, and this MST can be cultured, expanded and genetically modified while preserving its rapid haematopoietic engraftment potential. These results support the consideration of an MST approach for clinical translation, especially for gene therapy approaches that require HSC compartment modification.

  Feb. 2022, British journal of haematology, 196(3) (3), 711 - 723, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Establishment of a Predictive Model for GvHD-free, Relapse-free Survival after Allogeneic HSCT using Ensemble Learning.

  Makoto Iwasaki, Junya Kanda, Yasuyuki Arai, Tadakazu Kondo, Takayuki Ishikawa, Yasunori Ueda, Kazunori Imada, Takashi Akasaka, Akihito Yonezawa, Kazuhiro Yago, Masaharu Nohgawa, Naoyuki Anzai, Toshinori Moriguchi, Toshiyuki Kitano, Mitsuru Itoh, Nobuyoshi Arima, Tomoharu Takeoka, Mitsumasa Watanabe, Hirokazu Hirata, Kosuke Asagoe, Isao Miyatsuka, Le My An, Masanori Miyanishi, Akifumi Takaori-Kondo

  Graft-versus-host-disease-free, relapse-free survival (GRFS) is a useful composite endpoint that measures survival without relapse or significant morbidity after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to develop a novel analytical method that appropriately handles right-censored data and competing risks to understand the risk for GRFS and each component of GRFS. This study was a retrospective data-mining study on a cohort of 2207 adult patients who underwent their first allo-HSCT at the Kyoto Stem Cell Transplantation Group (KSCTG), a multi-institutional joint research group of 17 transplantation centers in Japan. The primary endpoint was GRFS. A stacked ensemble of Cox proportional hazard regression and seven machine learning algorithms was applied to develop a prediction model. The median age of patients was 48 years. For GRFS, the stacked ensemble model achieved better predictive accuracy evaluated by C-index than other top-of-the-art competing risk models (ensemble model: 0.670, Cox-PH: 0.668, Random Survival Forest: 0.660, Dynamic DeepHit: 0.646). The probability of GRFS after 2 years was 30.54% for the high-risk and 40.69% for the low-risk group, respectively (hazard ratio [HR] compared to the low-risk group: 2.127; 95% CI: 1.19-3.80). We developed a novel predictive model for survival analysis that showed superior risk stratification to existing methods using a stacked ensemble of multiple machine learning algorithms.

  Dec. 2021, Blood advances, English, International magazine

  [Refereed]

  Scientific journal


• Hoxb5 defines the heterogeneity of self-renewal capacity in the hematopoietic stem cell compartment.

  Taro Sakamaki, Kevin S Kao, Katsuyuki Nishi, James Y Chen, Kay Sadaoka, Momo Fujii, Akifumi Takaori-Kondo, Irving L Weissman, Masanori Miyanishi

  Self-renewal and multipotency are essential functions of hematopoietic stem cells (HSCs). To maintain homeostatic hematopoiesis, functionally uniform HSCs have been thought to be an ideal cell-of-origin. Recent technological advances in the field have allowed us to analyze HSCs with single cell resolution and implicate that functional heterogeneity may exist even within the highly purified HSC compartment. However, due in part to the technical limitations of analyzing extremely rare populations and our incomplete understanding of HSC biology, neither the biological meaning of why heterogeneity exists nor the precise mechanism of how heterogeneity is determined within the HSC compartment is entirely known. Here we show the first evidence that self-renewal capacity varies with the degree of replication stress dose and results in heterogeneity within the HSC compartment. Using the Hoxb5-reporter mouse line which enables us to distinguish between long-term (LT)-HSCs and short-term (ST)-HSCs, we have found that ST-HSCs quickly lose self-renewal capacity under high stress environments but can maintain self-renewal under low stress environments for long periods of time. Critically, exogeneous Hoxb5 expression confers protection against loss of self-renewal to Hoxb5-negative HSCs and can partially alter the cell fate of ST-HSCs to that of LT-HSCs. Our results demonstrate that Hoxb5 imparts functional heterogeneity in the HSC compartment by regulating self-renewal capacity. Additionally, Hoxb5-positive HSCs may exist as fail-safe system to protect from the exhaustion of HSCs throughout an organism's lifespan.

  Feb. 2021, Biochemical and biophysical research communications, 539, 34 - 41, English, International magazine

  [Refereed]

  Scientific journal


• Low Multiplication Value of Absolute Monocyte Count and Absolute Lymphocyte Count at Diagnosis May Predict Poor Prognosis in Neuroblastoma.

  Akihiro Tamura, Shotaro Inoue, Takeshi Mori, Jun Noguchi, Sayaka Nakamura, Atsuro Saito, Aiko Kozaki, Toshiaki Ishida, Kay Sadaoka, Daiichiro Hasegawa, Yoshiyuki Kosaka, Masanori Miyanishi

  Despite the growing evidences that immune dysfunction contributes to tumor progression, the prognostic value in patients with neuroblastoma regarding circulating immune blood cell counts has not been well characterized. To answer this, we conducted a retrospective study to evaluate the prognostic value of the circulating immune cell counts at diagnosis in a cohort of 55 patients with neuroblastoma. Based on a novel index by multiplying the absolute monocyte count (AMC)/μl and absolute lymphocyte count (ALC)/μl, we sub-grouped patients with AMC × ALC ≥ 1 × 106 (/μl)2 as high group and patients with AMC × ALC < 1 × 106 (/μl)2 as low group. In the entire cohort, the 4-year progression-free survival (PFS), and overall survival (OS) for high group (n = 38) vs low group (n = 17) was 81.7% (95%CI; 63.6-91.3%) and 90.7% (95%CI; 73.8-96.9%) vs 31.7% (11.6-54.1%) and 56.5% (29.7-76.4%; p < 0.001 for PFS and p = 0.015 for OS), respectively, suggesting that a low AMC × ALC is associated with poor prognosis. In the subgroup analysis for high-risk patients, the 4-year PFS and OS for high group (n = 17) vs low group (n = 13) was 59.8% (31.2-79.7%) and 79.8% (49.4-93.0%) vs 8.5% (0.5-31.7%) and 42.0% (15.4-66.8%; p < 0.001 for PFS and p = 0.089 for OS), respectively. Our data demonstrate that AMC × ALC at diagnosis is a cost-effective and easily measurable biomarker for predicting prognosis in neuroblastoma.

  2020, Frontiers in oncology, 10, 572413 - 572413, English, International magazine

  [Refereed]

  Scientific journal


• Neutrophil and monocyte kinetics play critical roles in mouse peritoneal adhesion formation.

  Tsai JM, Shoham M, Fernhoff NB, George BM, Marjon KD, McCracken MN, Kao KS, Sinha R, Volkmer AK, Miyanishi M, Seita J, Rinkevich Y, Weissman IL

  Sep. 2019, Blood advances, 3(18) (18), 2713 - 2721

  [Refereed]


• Galactosyl carbohydrate residues on hematopoietic stem/progenitor cells are essential for homing and engraftment to the bone marrow.

  Soichiro Takagaki, Rieko Yamashita, Noriyoshi Hashimoto, Kazushi Sugihara, Kanako Kanari, Keisuke Tabata, Toshikazu Nishie, Shogo Oka, Masanori Miyanishi, Chie Naruse, Masahide Asano

  The role of carbohydrate chains in leukocyte migration to inflamed sites during inflammation and trafficking to the lymph nodes under physiological conditions has been extensively characterized. Here, we report that carbohydrate chains also mediate the homing and engraftment of hematopoietic stem/progenitor cells (HSPCs) to the bone marrow (BM). In particular, we found that transplanted BM cells deficient in β-1,4-galactosyltransferase-1 (β4GalT-1) could not support survival in mice exposed to a lethal dose of irradiation. BM cells obtained from mice deficient in β4GalT-1 showed normal colony-forming activity and hematopoietic stem cell numbers. However, colony-forming cells were markedly rare in the BM of recipient mice 24 h after transplantation of β4GalT-1-deficient BM cells, suggesting that β4GalT-1 deficiency severely impairs homing. Similarly, BM cells with a point mutation in the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene, encoding a key enzyme in sialic acid biosynthesis, showed mildly impaired homing and engraftment abilities. These results imply that the galactosyl, but not sialyl residues in glycoproteins, are essential for the homing and engraftment of HSPCs to the BM. These findings suggest the possibility of modifying carbohydrate structures on the surface of HSPCs to improve their homing and engraftment to the BM in clinical application.

  May 2019, Scientific reports, 9(1) (1), 7133 - 7133, English, International magazine

  [Refereed]

  Scientific journal


• [Significance and purification of long-term hematopoietic stem cells in the hematopoietic system].

  Sakamaki T, Miyanishi M

  2019, [Rinsho ketsueki] The Japanese journal of clinical hematology, 60(9) (9), 1056 - 1062

  [Refereed]


• Where Hematopoietic Stem Cells Live: The Bone Marrow Niche.

  Szade K, Gulati GS, Chan CKF, Kao KS, Miyanishi M, Marjon KD, Sinha R, George BM, Chen JY, Weissman IL

  Jul. 2018, Antioxidants & redox signaling, 29(2) (2), 191 - 204

  [Refereed]


• Hoxb5 marks long-term haematopoietic stem cells and reveals a homogenous perivascular niche

  James Y. Chen, Masanori Miyanishi, Sean K. Wang, Satoshi Yamazaki, Rahul Sinha, Kevin S. Kao, Jun Seita, Debashis Sahoo, Hiromitsu Nakauchi, Irving L. Weissman

  Feb. 2016, NATURE, 530(7589) (7589), 223 - +, English

  [Refereed]

  Scientific journal


• Do Pluripotent Stem Cells Exist in Adult Mice as Very Small Embryonic Stem Cells?

  Masanori Miyanishi, Yasuo Mori, Jun Seita, James Y. Chen, Seth Karten, Charles K. F. Chan, Hiromitsu Nakauchi, Irving L. Weissman

  Aug. 2013, STEM CELL REPORTS, 1(2) (2), 198 - 208, English

  [Refereed]

  Scientific journal


• Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

  Diane Tseng, Jens-Peter Volkmer, Stephen B. Willingham, Humberto Contreras-Trujillo, John W. Fathman, Nathaniel B. Fernhoff, Jun Seita, Matthew A. Inlay, Kipp Weiskopf, Masanori Miyanishi, Irving L. Weissman

  Jul. 2013, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(27) (27), 11103 - 11108, English

  [Refereed]

  Scientific journal


• Synergistic effect of Tim4 and MFG-E8 null mutations on the development of autoimmunity

  Masanori Miyanishi, Katsumori Segawa, Shigekazu Nagata

  Sep. 2012, INTERNATIONAL IMMUNOLOGY, 24(9) (9), 551 - 559, English

  [Refereed]

  Scientific journal


• Engulfment of Apoptotic Cells and Its Physiological Roles

  Rikinari Hanayama, Masanori Miyanishi, Hiroshi Yamaguchi, Jun Suzuki, Shigekazu Nagata

  John Wiley & Sons, Ltd, Dec. 2009, Cell Death (Wiley), 165 - 175

  [Invited]


• Identification of Tim4 as a phosphatidylserine receptor

  Masanori Miyanishi, Kazutoshi Tada, Masato Koike, Yasuo Uchiyama, Toshio Kitamura, Shigekazu Nagata

  Nov. 2007, NATURE, 450(7168) (7168), 435 - 439, English

  [Refereed]

  Scientific journal


• Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition

  Tsukasa Baba, Masatoshi Kariya, Toshihiro Higuchi, Masaki Mandai, Noriomi Matsumura, Eiji Kondoh, Masanori Miyanishi, Ken Fukuhara, Kenji Takakura, Shingo Fujii

  Jun. 2007, GYNECOLOGIC ONCOLOGY, 105(3) (3), 703 - 711, English

  [Refereed]

  Scientific journal


• Immortalized ovarian surface epithelial cells acquire tumorigenicity by acrogranin gene overexpression

  Masanori Miyanishi, Masaki Mandai, Noriomi Matsumura, Ken Yamaguchi, Junzo Hamanishi, Toshihiro Higuchi, Kenji Takakura, Shingo Fujii

  Feb. 2007, ONCOLOGY REPORTS, 17(2) (2), 329 - 333, English

  [Refereed]

  Scientific journal


• Oncogenic property of acrogranin in human uterine leiomyosarcoma: Direct evidence of genetic contribution in vivo tumorigenesis

  N Matsumura, M Mandai, M Miyanishi, K Fukuhara, T Baba, T Higuchi, M Kariya, K Takakura, S Fujii

  Mar. 2006, CLINICAL CANCER RESEARCH, 12(5) (5), 1402 - 1411, English

  [Refereed]

  Scientific journal

• 免疫不全マウスモデルにおけるLineage特異的なin vivo細胞分化法に関する基礎的検討

  長坂明臣, 酒巻太郎, 宮西正憲

  2025, 日本再生医療学会総会(Web), 24th


• 10色超マルチカラーフローサイトメトリー法を用いたヒト骨髄由来間葉系幹細胞分画の不均一性の可視化

  田中秀弥, 宮西正憲, 西克幸, 酒巻太郎, 長坂昭臣, 美舩泰, 林申也, 松本知之, 黒田良祐

  2024, 日本整形外科学会雑誌(CD-ROM), 98(8) (8)


• 多層性解析によるヒト造血幹細胞単離法の最適化

  宮西正憲, 宮西正憲, 長坂明臣, 酒巻太郎, 西克幸, 塚本成幸, 定岡恵, 山本暢之, 井上翔太郎, MY An Le

  2024, 日本再生医療学会総会(Web), 23rd


• AI技術を用いたMDS患者骨髄細胞の解析

  増田健太, 中西加代子, 岩崎惇, 諫田淳也, 宮塚功, 宮西正憲, 高折晃史

  2024, 日本検査血液学会雑誌, 25


• Refractory Evans syndrome after allo-HSCT in a patient with chronic granulomatous disease

  植村優, 長谷川大一郎, 真鍋修司, 田中祐介, 西尾周朗, 堀川翔伍, 秋定直宏, 兵頭さやか, 神前愛子, 斎藤敦郎, 岸本健治, 石田敏章, 森健, 井上翔太郎, 宮西正憲, 小阪嘉之

  2024, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th


• 深層学習を用いたコロニー形成ユニット(CFU)アッセイの自動化

  中田光隆, TASAVAT Trisitichoke, 岡芳樹, 伊藤誉子, 稲垣翼, 陳静, 中原菜摘, 平木友理, 野田修志, 宮西正憲, 宮西正憲, 竹谷誠

  2023, 日本再生医療学会総会(Web), 22nd


• 多様性が求められる未来のARTについて 産婦人科出身造血幹細胞研究者が想造する未来医療

  宮西 正憲

  (一社)日本IVF学会, Sep. 2022, 日本IVF学会誌, 25(2) (2), 42 - 42, Japanese


• 小児悪性脳腫瘍の発症・進行メカニズムに関連した単球・マクロファージ系血細胞の多様性に関する基礎的研究

  長谷川 大一郎, 田村 彰広, 宮西 正憲, 小阪 嘉之

  (一社)兵庫県医師会, Mar. 2022, 兵庫県医師会医学雑誌, 64(2) (2), 35 - 35, Japanese


• 診断時単球絶対数とリンパ球絶対数の乗算低値は神経芽腫の予後不良に相関する(Low multiplication value of monocyte and lymphocyte count may be associated with poor prognosis in neuroblastoma)

  田村 彰広, 井上 翔太郎, 森 健, 中村 さやか, 齋藤 敦郎, 神前 愛子, 石田 敏章, 長谷川 大一郎, 小阪 嘉之, 宮西 正憲

  (公社)日本小児科学会, Feb. 2022, 日本小児科学会雑誌, 126(2) (2), 230 - 230, English


• 小児悪性脳腫瘍の発症・進行メカニズムに関連した単球・マクロファージ系血細胞の多様性に関する基礎的研究

  長谷川大一郎, 田村彰広, 宮西正憲, 小阪嘉之

  2022, 兵庫県医師会医学雑誌, 64(2) (2)


• Low multiplication value of monocyte and lymphocyte count may be associated with poor prognosis in neuroblastoma

  田村彰広, 田村彰広, 井上翔太郎, 森健, 中村さやか, 齋藤敦郎, 神前愛子, 石田敏章, 長谷川大一郎, 小阪嘉之, 宮西正憲

  2022, 日本小児科学会雑誌, 126(2) (2)


• 産婦人科出身造血幹細胞研究者が想造する未来医療

  宮西正憲

  2022, 日本IVF学会雑誌, 25(2) (2)


• C/EBPβ依存的非古典的単球の制御による新規小児がん治療法開発

  田村彰広, 宮西正憲

  2022, 小児医学研究振興財団研究報告書, 2020


• ヒト造血幹細胞機能維持細胞増幅培養液の開発

  森田 寛之, 塚本 成幸, 宮西 正憲, 竹谷 誠

  (一社)日本組織培養学会, Aug. 2021, 組織培養研究, 39(1) (1), 93 - 93, Japanese


• Establishment of a Predictive Model for GRFS after Allo-HSCT using Ensemble Learning

  岩崎惇, 岩崎惇, 諫田淳也, 諫田淳也, 新井康之, 新井康之, 近藤忠一, 近藤忠一, 石川隆之, 石川隆之, 上田恭典, 上田恭典, 今田和典, 今田和典, 赤坂尚司, 赤坂尚司, 米澤昭仁, 米澤昭仁, 野吾和宏, 野吾和宏, 直川匡晴, 直川匡晴, 安齋尚之, 安齋尚之, 森口寿徳, 森口寿徳, 北野俊行, 北野俊行, 伊藤満, 伊藤満, 有馬靖佳, 有馬靖佳, 竹岡友晴, 竹岡友晴, 渡邊光正, 渡邊光正, 平田大二, 平田大二, 浅越康助, 浅越康助, 宮西正憲, 宮塚功, AN Le My, 高折晃史, 高折晃史

  2021, 日本造血細胞移植学会総会プログラム・抄録集, 43rd


• Development of proliferation and maintenance medium for human hematopoietic stem cells

  森田寛之, 塚本成幸, 宮西正憲, 竹谷誠

  2021, 組織培養研究(Web), 39(1) (1)


• The cell fate of HSCs is regulated flexibly by hematopoietic stress

  酒巻太郎, 西克幸, 西克幸, 定岡恵, 藤井桃, 宮西正憲

  2021, 日本血液学会学術集会抄録(Web), 83rd


• Alteration of the short/long-term hematopoietic stem cell ratio causes lineage-biased hematopoiesis

  西克幸, 西克幸, 酒巻太郎, 酒巻太郎, KAO Kevin, 定岡恵, 藤井桃, 高折晃史, 宮西正憲

  2021, 日本血液学会学術集会抄録(Web), 83rd


• Nanoimprint lithographyと完全溶融式射出成形機を用いた新しい成形加工技術の開発

  高橋泰輔, 高橋泰輔, 土田新, 新宅博文, 宮西正憲, 須藤詩乃, 田口瑠南, 海邊政哉, 安田玲子, 黒澤修, 小此木孝仁, 西村文仁

  2021, 化学とマイクロ・ナノシステム学会研究会講演要旨集(CD-ROM), 44th


• 希少細胞集団をターゲットにした高感度ChIP-Seq解析法の開発

  宮西正憲

  2020, ライフサイエンス振興財団助成成果報告書, 2019


• C/EBPβ依存的非古典的単球の制御による新規小児がん治療法開発

  田村 彰広, 宮西 正憲

  [東京] : 小児医学研究振興財団, 2020, 公益財団法人小児医学研究振興財団研究報告書, 12 - 14, Japanese


• 造血系における長期造血幹細胞の意義と純化システム

  酒巻 太郎, 宮西 正憲

  (一社)日本血液学会-東京事務局, Sep. 2019, 臨床血液, 60(9) (9), 1056 - 1062, Japanese


• Significance and purification of long-term hematopoietic stem cells in the hematopoietic system

  SAKAMAKI Taro, MIYANISHI Masanori

  The hematopoietic stem cells, defined as blood stem cells with self-replication ability and multipotency, are key to successful hematopoietic stem cell transplantation. With the history of transplantation in the past 60 years and advances in stem cell technologies, our understanding of the hematopoietic system has deepened. However, the molecular mechanisms of self-renewal and pluripotency, which are the essence of the hematopoietic stem cells, remain poorly understood. One reason is that the identification/purification methods of the hematopoietic stem cells, particularly the long-term hematopoietic stem cells capable of lifelong self-renewal, is technically difficult owing to their scarcity in the bone marrow and has not been established to this date. Considering that a long-lasting blood production after hematopoietic stem cell transplantation is crucial, it is essential to understand the biology of the long-term hematopoietic stem cells not only scientifically but also clinically. This review describes the scientific and clinical significance of the long-term hematopoietic stem cells by showing the results of the latest researches in the introduction of hematopoietic stem cell identification/purification history.

  The Japanese Society of Hematology, 2019, Rinsho Ketsueki, 60(9) (9), 1056 - 1062, Japanese

  [Refereed]


• Significance and purification of long-term hematopoietic stem cells in the hematopoietic system

  酒巻太郎, 宮西正憲

  2019, 臨床血液, 60(9) (9)


• 造血幹細胞のホーミングおよび分化におけるB4Galt1の役割

  山下莉映子, 山下莉映子, 成瀬智恵, 杉原一司, 金成香奈子, 高垣聡一郎, 宮西正憲, 岡昌吾, 浅野雅秀

  2019, 日本実験動物学会総会講演要旨集(Web), 66th


• P1-118 上皮性卵巣癌におけるtrophininの発現意義(Group 16 卵巣腫瘍I,一般演題,講演要旨,第58回日本産科婦人科学会学術講演会)

  馬場,長, 刈谷,方俊, 宮西,正憲, 山田,重人, 松村,謙臣, 鈴木,彩子, 八木,治彦, 福原,健, 万代,昌紀, 樋口,壽宏, 高倉,賢二, 藤井,信吾

  日本産科婦人科学会, 01 Feb. 2006, 日本産科婦人科學會雜誌, 58(2) (2), 410, Japanese


• P1-118 上皮性卵巣癌におけるtrophininの発現意義(Group 16 卵巣腫瘍I,一般演題,講演要旨,第58回日本産科婦人科学会学術講演会)

  馬場,長, 刈谷,方俊, 宮西,正憲, 山田,重人, 松村,謙臣, 鈴木,彩子, 八木,治彦, 福原,健, 万代,昌紀, 樋口,壽宏, 高倉,賢二, 藤井,信吾

  日本産科婦人科学会, 01 Feb. 2006, 日本産科婦人科學會雜誌, 58(2) (2), 410, Japanese


• 上皮性卵巣癌におけるtrophininの発現意義

  馬場 長, 刈谷 方俊, 宮西 正憲, 山田 重人, 松村 謙臣, 鈴木 彩子, 八木 治彦, 福原 健, 万代 昌紀, 樋口 壽宏, 高倉 賢二, 藤井 信吾

  (公社)日本産科婦人科学会, Feb. 2006, 日本産科婦人科学会雑誌, 58(2) (2), 410 - 410, Japanese


• 上皮性卵巣癌におけるtrophininの発現意義

  馬場長, 刈谷方俊, 宮西正憲, 山田重人, 松村謙臣, 鈴木彩子, 八木治彦, 福原健, 万代昌紀, 樋口寿宏, 高倉賢二, 藤井信吾

  2006, 日本産科婦人科学会雑誌, 58(2) (2)


• hTERTとSV40LT抗原によって不死化した卵巣表層上皮細胞は Acrogranin の遺伝子導入によって足場非依存性増殖が促進される(卵巣腫瘍II, 第57回日本産科婦人科学会学術講演会)

  万代,昌紀, 松村,謙臣, 宮西,正憲, 近藤,英治, 山田,重人, 志馬,裕明, 金森,崇修, 福原,健, 樋口,壽宏, 刈谷,方俊, 高倉,賢二, 藤井,信吾

  日本産科婦人科学会, 01 Feb. 2005, 日本産科婦人科學會雜誌, 57(2) (2), 454, Japanese


• 細胞障害性T細胞を効率的に活性化する樹状細胞を作成するためのFLT3 Ligand 発現フィーダー細胞の作成(悪性腫瘍全般I, 第57回日本産科婦人科学会学術講演会)

  松村,謙臣, 万代,昌紀, 宮西,正憲, 佐藤,寛, 山田,重人, 堀内,由佳, 金森,崇修, 福原,健, 樋口,壽宏, 刈谷,方俊, 高倉,賢二, 藤井,信吾

  日本産科婦人科学会, 01 Feb. 2005, 日本産科婦人科學會雜誌, 57(2) (2), 469, Japanese


• 子宮平滑筋肉腫における Acrogranin 過剰発現と組織学的悪性度との相関(子宮体部悪性腫瘍X, 第57回日本産科婦人科学会学術講演会)

  樋口,壽宏, 松村,謙臣, 万代,昌紀, 宮西,正憲, 馬場,長, 山田,重人, 堀内,由佳, 門間,千佳, 福原,健, 刈谷,方俊, 高倉,賢二, 藤井,信吾

  日本産科婦人科学会, 01 Feb. 2005, 日本産科婦人科學會雜誌, 57(2) (2), 610, Japanese


• リンパ球と共培養することで, 細胞障害性T細胞の活性を高めるフィーダー細胞の作成(悪性腫瘍全般I, 第57回日本産科婦人科学会学術講演会)

  宮西,正憲, 松村,謙臣, 万代,昌紀, 馬場,長, 近藤,英治, 門間,千佳, 堀内,由佳, 福原,健, 樋口,壽宏, 刈谷,方俊, 高倉,賢二, 藤井,信吾

  日本産科婦人科学会, 01 Feb. 2005, 日本産科婦人科學會雜誌, 57(2) (2), 469, Japanese


• リンパ球と共培養することで, 細胞障害性T細胞の活性を高めるフィーダー細胞の作成(悪性腫瘍全般I, 第57回日本産科婦人科学会学術講演会)

  宮西,正憲, 松村,謙臣, 万代,昌紀, 馬場,長, 近藤,英治, 門間,千佳, 堀内,由佳, 福原,健, 樋口,壽宏, 刈谷,方俊, 高倉,賢二, 藤井,信吾

  日本産科婦人科学会, 01 Feb. 2005, 日本産科婦人科學會雜誌, 57(2) (2), 469, Japanese


• hTERTとSV40LT抗原によって不死化した卵巣表層上皮細胞はAcrograninの遺伝子導入によって足場非依存性増殖が促進される

  万代 昌紀, 松村 謙臣, 宮西 正憲, 近藤 英治, 山田 重人, 志馬 裕明, 金森 崇修, 福原 健, 樋口 壽宏, 刈谷 方俊, 高倉 賢二, 藤井 信吾

  (公社)日本産科婦人科学会, Feb. 2005, 日本産科婦人科学会雑誌, 57(2) (2), 454 - 454, Japanese


• 子宮平滑筋肉腫におけるAcrogranin過剰発現と組織学的悪性度との相関

  樋口 壽宏, 松村 謙臣, 万代 昌紀, 宮西 正憲, 馬場 長, 山田 重人, 堀内 由佳, 門間 千佳, 福原 健, 刈谷 方俊, 高倉 賢二, 藤井 信吾

  (公社)日本産科婦人科学会, Feb. 2005, 日本産科婦人科学会雑誌, 57(2) (2), 610 - 610, Japanese


• 細胞障害性T細胞を効率的に活性化する樹状細胞を作成するためのFLT3 Ligand発現フィーダー細胞の作成

  松村 謙臣, 万代 昌紀, 宮西 正憲, 佐藤 寛, 山田 重人, 堀内 由佳, 金森 崇修, 福原 健, 樋口 壽宏, 刈谷 方俊, 高倉 賢二, 藤井 信吾

  (公社)日本産科婦人科学会, Feb. 2005, 日本産科婦人科学会雑誌, 57(2) (2), 469 - 469, Japanese


• 子宮平滑筋肉腫におけるAcrogranin過剰発現と組織学的悪性度との相関

  樋口寿宏, 松村謙臣, 万代昌紀, 宮西正憲, 馬場長, 山田重人, 堀内由佳, 門間千佳, 福原健

  2005, 日本産科婦人科学会雑誌, 57(2) (2)


• 難治性卵巣癌に対する取り組み リンパ節転移症例を中心に

  平野 剛, 永野 忠義, 宮西 正憲, 榊原 敦子, 高橋 秀元, 岡垣 篤彦, 伴 千秋

  上皮性卵巣癌167例のうち,リンパ節郭清を107例に施行した.pT3症例でも65例中25例に施行し,その48%にリンパ節転移を認めた.FIGO進行期別の5年生存率は,III期では38%と不良であった.pT1症例とpT3症例を比較するとN1,N0,Nxで有意差はなかったが,pT1症例は5年を越えるとN1症例に死亡が増え,殆どが多発リンパ節転移例であった.pT3症例のうちM1を除く62例では,初回手術がoptimal手術となったのは17例で,再手術を含めると32例であった.suboptimal手術に終わった明細胞癌は化学療法に抵抗し,再手術例はなかった.手術完遂度別の5年生存率は,optimal手術例が42%,suboptimal手術例が26%と差があったが,長期追跡では予後の差はなかった.なおpT3症例において,リンパ節転移の有無で5年生存率を検討したが,有意差は認めず,化学療法の種類でも有意差はなかった

  「産婦人科の進歩」編集室, Aug. 2004, 産婦人科の進歩, 56(3) (3), 332 - 335, Japanese


• 下垂体腺腫により惹起された両側多嚢胞性卵巣腫瘤の1例

  今岡 いずみ, 和田 昭彦, 松尾 導昌, 宮西 正憲, 吉田 益美, 欅 篤, 鍋島 祥男

  バイエル薬品(株), Apr. 2004, 日独医報, 49(1) (1), 147 - 147, Japanese


• 腹水細胞診陽性の子宮体癌をいかに取り扱うか

  高橋 秀元, 永野 忠義, 宮西 正憲, 榊原 敦子, 平野 剛, 岡垣 篤彦, 伴 千秋

  「産婦人科の進歩」編集室, Apr. 2004, 産婦人科の進歩, 56(2) (2), 237 - 237, Japanese


• 4年間の経過観察後に手術に至った子宮平滑筋肉腫の1例

  永野 忠義, 宮西 正憲, 榊原 敦子, 高橋 秀元, 平野 剛, 岡垣 篤彦, 伴 千秋, 真能 正幸, 高田 賀章

  「産婦人科の進歩」編集室, Apr. 2004, 産婦人科の進歩, 56(2) (2), 259 - 259, Japanese


• 21-3.卵巣がんに対するPaclitaxel, Carboplatin併用化学療法(TC療法)(第99群 卵巣腫瘍10(多施設))(一般演題)

  宮西,正憲

  日本産科婦人科学会, 01 Feb. 2004, 日本産科婦人科學會雜誌, 56(2) (2), 575, Japanese


• 卵巣がんに対するPaclitaxel,Carboplatin併用化学療法(TC療法)

  宮西 正憲

  (公社)日本産科婦人科学会, Feb. 2004, 日本産科婦人科学会雑誌, 56(2) (2), 575 - 575, Japanese


• Retrospective analysis of treatment outcome in high risk advanced ovarian cancer

  HIRANO Takeshi, NAGANO Tadayoshi, MIYANISHI Masanori, SAKAKIBARA Atsuko, TAKAHASHI Shugen, OKAGAKI Atsuhiko, BAN Chiaki

  THE OBSTETRICAL GYNECOLOGICAL SOCIETY OF KINKI DISTRICT JAPAN, 2004, ADVANCES IN OBSTETRICS AND GYNECOLOGY, 56(3) (3), 332 - 335, Japanese


• 子宮内膜腺線維腫(adenofibroma)内に発生したと思われる類内膜腺癌の一例

  宮西 正憲, 荒川 奈央子, 榊原 敦子, 高橋 秀元, 平野 剛, 岡垣 篤彦, 永野 忠義, 伴 千秋, 鈴木 暸

  「産婦人科の進歩」編集室, Nov. 2003, 産婦人科の進歩, 55(4) (4), 499 - 499, Japanese


• 難治性卵巣癌に対する取り組み リンパ節転移症例を中心に

  平野 剛, 永野 忠義, 荒川 奈央子, 宮西 正憲, 榊原 敦子, 高橋 秀元, 岡垣 篤彦, 伴 千秋, 鈴木 暸

  「産婦人科の進歩」編集室, Nov. 2003, 産婦人科の進歩, 55(4) (4), 526 - 526, Japanese


• 子宮体部類内膜腺癌術後早期に腹腔内に漿液性腺癌を発症した症例

  荒川 奈央子, 永野 忠義, 宮西 正憲, 榊原 敦子, 高橋 秀元, 平野 剛, 伴 千秋, 鈴木 暸, 河原 邦光, 倉田 明彦

  (公社)日本婦人科腫瘍学会, Jun. 2003, 日本婦人科腫瘍学会雑誌, 21(3) (3), 238 - 238, Japanese


• 集学的治療により臨床的CRを得た進行子宮体部癌肉腫の1例

  宮西 正憲, 中村 郁, 野口 明子, 南野 英隆, 林 道治, 吉田 益美

  「産婦人科の進歩」編集室, Nov. 2002, 産婦人科の進歩, 54(6) (6), 518 - 518, Japanese


• 進行子宮頸癌の治療における術前放射線療法の役割について

  野口 明子, 中村 郁, 宮西 正憲, 南野 英隆, 林 道治, 吉田 益美

  「産婦人科の進歩」編集室, Nov. 2002, 産婦人科の進歩, 54(6) (6), 527 - 527, Japanese


• 塩酸イリノテカン投与後に重篤な大腸炎をきたした再発卵巣癌の一症例

  中村 郁, 宮西 正憲, 野口 明子, 南野 英隆, 林 道治, 吉田 益美

  「産婦人科の進歩」編集室, Nov. 2002, 産婦人科の進歩, 54(6) (6), 536 - 536, Japanese


• 肉眼的及び病理学的特徴より見たMRI画像情報の検討 卵巣悪性胚細胞腫瘍に関して

  宮西 正憲, 中村 郁, 野口 明子, 南野 英隆, 林 道治, 吉田 益美, 今岡 いずみ, 小橋 陽一郎

  「産婦人科の進歩」編集室, May 2002, 産婦人科の進歩, 54(3) (3), 268 - 268, Japanese


• 下垂体腺腫による高プロラクチン血症がhyperreactio luteinalis-like patternを惹起したと考えられる両側多発性卵巣嚢腫の1例

  宮西正憲, 今岡いずみ, 中村郁, 野口明子, 南野英隆, 林道治, 吉田益美, 和田昭彦, 松尾導昌

  2002, Abstracts. Annual Symposium. Japanese Society for the Advancement of Women’s Imaging, 3rd (Web)


• 感覚性ニューロパチーを先行症状とした子宮体部小細胞癌の一例

  吉田 益美, 宮西 正憲, 野口 明子, 森田 康史, 南野 英隆, 林 道治, 中村 道三, 今岡 いずみ, 弓場 吉哲

  「産婦人科の進歩」編集室, Nov. 2001, 産婦人科の進歩, 53(6) (6), 560 - 560, Japanese


• 子宮体癌進展度と術前腫瘍マーカー値の関連性の検討

  住友 理浩, 樋口 壽宏, 加藤 倫隆, 宮西 正憲, 吉岡 弓子, 万代 昌紀, 北 正人, 刈谷 方俊, 藤井 信吾

  「産婦人科の進歩」編集室, May 2000, 産婦人科の進歩, 52(3) (3), 600 - 600, Japanese


• 婦人科腫瘍性疾患の術前評価におけるPositron Emission Tomography(PET)の有用性の検討

  宮西 正憲, 樋口 壽宏, 万代 昌紀, 姜 賢淑, 野口 明子, 住友 理浩, 刈谷 方俊, 藤井 信吾, 中本 裕士

  「産婦人科の進歩」編集室, Nov. 1999, 産婦人科の進歩, 51(6) (6), 641 - 641, Japanese

• Cloning of Anti‑Nephrin Antibodies and Epitope Mapping of Nephrin Antigens in Pediatric Nephrotic Syndrome Patients

  飯島 一誠, 堀之内 智子, 野津 寛大, 宮西 正憲

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Kobe University, 01 Apr. 2026 - 31 Mar. 2029


• 造血幹細胞機能維持体外細胞増幅技術の開発

  宮西 正憲

  科学技術振興機構, 戦略的な研究開発の推進 創発的研究支援事業, 神戸大学, 2023 - 2029, Principal investigator

  造血幹細胞を用いた細胞・再生医療は、白血病などの悪性の血液疾患以外にも、遺伝子改変技術等を組み合わせることで、将来的には様々な難治性疾患を根治しうることが期待されています。その一方で、造血幹細胞が生体内にごく僅かしか存在せず細胞の調整そのものが容易でないことが、これら夢の技術開発の大きな障害となっています。そこで本研究では、これらの医療技術開発に革新をもたらす体外細胞増幅技術の開発を目指します。


• 末梢血・脱落膜免疫細胞プロファイル網羅的解析による不育症関連免疫異常の病態解析

  出口 雅士, 益子 尚久, 今福 仁美, 宮西 正憲, 谷村 憲司, 寺井 義人

  日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2025 - 31 Mar. 2028


• 造血系恒常性の維持から破綻に至るメカニズムの解明

  宮西 正憲

  日本学術振興会, 科学研究費助成事業, 基盤研究(B), 神戸大学, 01 Apr. 2025 - 31 Mar. 2028


• Elucidation of the mechanism of rituximab-induced long-term remission in childhood nephrotic syndrome

  飯島 一誠, 堀之内 智子, 野津 寛大, 宮西 正憲

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Kobe University, 01 Apr. 2023 - 31 Mar. 2026

• 造血幹細胞含有組成物

  宮西 正憲, 西 克幸

  特願2021-174101, 25 Oct. 2021, 国立研究開発法人理化学研究所, 特開2023-063965, 10 May 2023

  Patent right

  IRI


• 血液疾患の予後予測情報の生成システム、情報処理装置、サーバ、プログラム、又は方法

  宮西 正憲, 中島 正和, 宮塚 功, リー マイ アン, 諫田 淳也, ▲高▼折 晃史

  特願2019-011392, 25 Jan. 2019, 国立大学法人京都大学, 特開2020-119383, 06 Aug. 2020, 特許第7273393号, 02 May 2023

  Patent right

  IRI


• 造血幹細胞培養組成物

  森田 寛之, 竹谷 誠, 宮西 正憲

  特願2021-142790, 01 Sep. 2021, ネクスジェン株式会社, 特開2023-035731, 13 Mar. 2023

  Patent right

  IRI


• ヒト長期造血幹細胞マーカー

  宮西 正憲, 宮塚 功, リー マイ アン

  JP2021025050, 01 Jul. 2021, ネクスジェン株式会社, 特許第7215776号, 23 Jan. 2023

  Patent right

  IRI


• ヒト長期造血幹細胞マーカー

  宮西 正憲, 宮塚 功, リー マイ アン

  特願2022-040623, 15 Mar. 2022, ネクスジェン株式会社, 特開2022-179822, 05 Dec. 2022

  Patent right

  IRI


• 細胞評価、分類または純化装置、システムおよび方法。

  宮西 正憲, 宮塚 功, リー マイ アン

  特願2020-175244, 19 Oct. 2020, ネクスジェン株式会社, 特開2022-066730, 02 May 2022

  Patent right

  IRI


• 最適化された標識を用いて特異的に発現する遺伝子を同定する方法

  宮西 正憲, チェン,ジェームズ・ワイ.

  特願2016-210347, 27 Oct. 2016, ネクスジェン株式会社, 特開2018-068178, 10 May 2018, 特許第7064732号, 27 Apr. 2022

  Patent right

  IRI


• 最適化された標識を用いて特異的に発現する遺伝子を同定する方法

  宮西 正憲, チェン,ジェームズ・ワイ.

  特願2021-167686, 12 Oct. 2021, ネクスジェン株式会社, 特開2022-023121, 07 Feb. 2022

  Patent right

  IRI